8-K current report · filed Sep 30, 2026

STANDARD BIOTOOLS INC. (LAB) 8-K Current Report: September 30, 2026

Item 1.01Item 7.01Item EX-99.1Item 1.02LAB overview

Short answer

STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 1.02 (Termination of a Material Definitive Agreement). Mass cytometry business sale shifted from Multiplex Bio to Element Biosystems, following a superior proposal from GMT Venture.

STANDARD BIOTOOLS INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Mass cytometry business sale shifted from Multiplex Bio to Element Biosystems, following a superior proposal from GMT Venture
  • Element purchase price: $5.5 million cash, cash-free and debt-free, subject to customary adjustments
  • Company owes Multiplex Bio a $1.5 million termination fee, with GMT Venture contributing $1.0 million
  • Closing requires stockholder approval, completion of the Treeline merger and other customary conditions
  • Potential downside: $1.0 million Element termination fee plus up to $250,000 expense reimbursement if the transaction fails under specified conditions

Item 1.02 · Termination of a Material Definitive Agreement

  • Item 1.02 references Item 1.01 for termination details of the Multiplex Bio Purchase Agreement
  • Agreement terms remain governed by the July 28, 2026 filing and July 29, 2026 amendment
  • Investors should review Item 1.01 and Exhibit 2.1 for the termination’s financial and strategic implications

Item 7.01 · Regulation FD Disclosure

  • September 30, 2026 press release announces proposed Business sale and Treeline merger transactions
  • Both transactions require stockholder approvals, creating execution and timing risk
  • Potential outcomes include termination fees, competing bids, litigation costs and unexpected liabilities
  • Proposed transactions could affect Nasdaq listing, employee retention, customer relationships and management focus

Item EX-99.1 · Exhibit EX-99.1

  • Multiplex Bio sale terminated; Mass Cytometry business sold to GMT Venture’s Element Biosystems for $5.5 million cash
  • Avoiding Multiplex’s required $10 million working-capital loan improves Treeline merger exchange-ratio net cash by approximately $15 million
  • Element transaction and Treeline merger both expected to close by end of 2026, subject to stockholder approval and customary conditions
  • Sale transfers CyTOF, Hyperion, and Maxpar platforms while preserving customer and team continuity under new ownership

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STANDARD BIOTOOLS INC. 8-K filings

Get the next LAB 8-K as it lands

Follow LAB for push alerts, or ask the research agent what this filing means.